Copyright
©The Author(s) 2023.
World J Diabetes. Aug 15, 2023; 14(8): 1289-1300
Published online Aug 15, 2023. doi: 10.4239/wjd.v14.i8.1289
Published online Aug 15, 2023. doi: 10.4239/wjd.v14.i8.1289
Figure 1 PRISMA summarizing the trial flow.
Figure 2 Results of the risk of bias in non-randomized studies of interventions tool for the extracted articles.
Figure 3 Forest plots and meta-analyses results.
A: The occurrence of death after any hepatocellular carcinoma (HCC) treatment and only after curative therapies: Metformin vs no metformin in type 2 diabetes mellitus (T2DM) patients; B: The occurrence of progressive tumor disease and HCC recurrence after any HCC treatment: Metformin vs no metformin in T2DM patients. HCC: Hepatocellular carcinoma.
Figure 4 Funnel plot of the studies selected in the present meta-analysis.
- Citation: Cigrovski Berkovic M, Giovanardi F, Mrzljak A, Lai Q. Prognostic role of metformin in diabetes mellitus type 2 patients with hepatocellular carcinoma: A systematic review and meta-analysis. World J Diabetes 2023; 14(8): 1289-1300
- URL: https://www.wjgnet.com/1948-9358/full/v14/i8/1289.htm
- DOI: https://dx.doi.org/10.4239/wjd.v14.i8.1289